top of page

Robert Tamillo, CCIM

Founder & Principal

With over 15 years of experience, in his role as Managing Director with JLL, Robert is responsible for creating and managing national corporate relationships & implementing real estate portfolio strategies on behalf of his clients.  He represents local and national industrial occupiers, including Fortune 500 organizations.  Projects may involve site selection, workforce analysis, market assessments, supply chain & logistics network studies; and negotiations of acquisitions & dispositions of commercial & industrial real estate.  Robert has served as a strategic adviser to various industries including diversified services firms, law firms, distribution, logistics, retail/e-commerce, manufacturing, energy and government institutions.   Over his career he has transacted projects valued in excess of $1.0B. 

 

Prior to joining JLL, Robert was with Sheldon Good & Company, one of the world's largest real estate auction firms followed by DTZ since 2006 (formerly Equis Corporation and now Cushman & Wakefield) providing tenant representation advisory services and was recognized as a top producer, aiding in the growth of DTZ’s industrial occupier business.

 

  • Certified Commercial Investment Member (CCIM)

  • Council of Supply Chain Management Professionals (CSCMP)

  • Illinois Real Estate License

  • Association of Industrial Real Estate Brokers (AIRE)

  • Member NAIOP Chicago

  • National Association of Realtors

 

Education

B.S. Management, School of Public and Environmental Affairs, Indiana University

Business Foundations, Kelley School of Business

Lorenzo de'Medici, Florence, Italy

 

Robert is an avid adventurer, exploring other cultures and parts of the world such as South Africa and multiple European destinations.  He supports Save the Rhino International, a non-profit organization focused on the conservation of rhinos internationally.  He is involved in local Chicago organizations as well as, the National Multiple Sclerosis Society, that funds the advancement of research for Multiple Sclerosis. 

bottom of page